Company Overview

Opus Genetics, Inc. is a privately held clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs), a group of rare, genetically driven eye disorders that can lead to progressive vision loss and blindness. The company operates within the biotechnology and ophthalmology gene therapy industries, with a core emphasis on precision genetic medicines designed to restore or preserve vision by addressing underlying monogenic defects.

The company’s primary value proposition is its targeted, disease-specific gene therapy programs aimed at well-characterized IRDs, including Leber congenital amaurosis and retinitis pigmentosa subtypes. Opus Genetics was founded to advance assets and scientific capabilities originally developed in academic and research settings, and it has evolved into a standalone company with an internal pipeline progressing through preclinical and clinical development stages, positioning itself as a focused player in the rare ophthalmic disease space.

Business Operations

Opus Genetics conducts its operations primarily through integrated research and development activities that span gene therapy design, preclinical validation, and clinical trial execution. Revenue generation is not currently based on commercialized products; instead, the company operates as a development-stage biotechnology firm funded through private capital, strategic financing, and research investments. Its core business revolves around advancing adeno-associated virus (AAV)-based gene therapy candidates for specific IRD indications.

Operationally, the company manages internal R&D functions while leveraging external manufacturing partners, contract research organizations, and clinical trial sites to support development. Opus Genetics does not publicly disclose multiple operating subsidiaries or diversified business units, and available public information indicates the company operates as a single focused entity dedicated to ophthalmic gene therapy development.

Strategic Position & Investments

Strategically, Opus Genetics is focused on building a pipeline of gene therapies targeting IRDs with clearly defined genetic causes, aiming to reduce development risk and increase regulatory clarity. Growth initiatives center on advancing lead programs into and through clinical trials, expanding the pipeline to additional retinal gene targets, and engaging with regulatory authorities to support eventual product approvals.

The company has made significant investments in proprietary gene therapy constructs and preclinical platforms tailored to retinal delivery. While Opus Genetics has not announced large-scale acquisitions or a diversified investment portfolio, it has selectively in-licensed or internally developed program assets and continues to invest in emerging gene therapy technologies relevant to retinal disease treatment. Data on additional acquisitions or minority investments is inconclusive based on available public sources.

Geographic Footprint

Opus Genetics is headquartered in the United States, with primary operations centered in North America. Its research, development, and corporate functions are largely U.S.-based, reflecting the concentration of biotechnology infrastructure, regulatory engagement, and clinical trial expertise in the region.

The company’s clinical and research activities extend internationally through collaborations with academic institutions, clinical investigators, and trial sites, particularly in regions with established ophthalmology research networks. While Opus Genetics does not maintain a broad commercial footprint across continents, its development programs are designed for global regulatory pathways and future international market access.

Leadership & Governance

Opus Genetics is led by an executive team with experience in gene therapy development, ophthalmology, and biotechnology commercialization. The leadership emphasizes a patient-focused, science-driven approach aimed at translating genetic research into clinically meaningful therapies for rare disease populations.

Key executives include:

• Ben Yerxa – Chief Executive Officer
• Shalesh Kaushal, MD, PhD – Founder and Chief Scientific Officer
• Michael Mullins – Chief Financial Officer

The leadership team’s strategic vision centers on disciplined clinical development, strong scientific validation, and long-term value creation through the successful advancement of gene therapies for inherited retinal diseases.